Esperion Therapeutics Inc.'s latest Phase III results for bempedoic acid in statin-intolerant patients with atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD met the LDL cholesterol-lowering primary endpoint and, importantly, didn't raise any new safety questions.
However, the data that may be most important for the oral therapy's commercial future aren't expected until August, when Esperion...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)